Market Cap 23.65B
Revenue (ttm) 3.81B
Net Income (ttm) -644.79M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 318.72
Profit Margin -16.92%
Debt to Equity Ratio 0.05
Volume 189,200
Avg Vol 468,388
Day's Range N/A - N/A
Shares Out 99.25M
Stochastic %K 82%
Beta 0.35
Analysts Strong Sell
Price Target $321.39

Company Profile

BeOne Medicines Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor o...

Industry: Biotechnology
Sector: Healthcare
Phone: 41 61 685 19 00
Address:
Aeschengraben 27, 21st Floor, Basel, Switzerland
SeniorVip
SeniorVip Jun. 24 at 1:10 PM
$IBRX $BMY is the one to acquire $IBRX not $AMGN nor $ONC . In 2019, $BMY acquired Celgene which had been acquired Abraxis BioScience in 2010 which was founded by Patrick Soon-Shiong in 2001. It is time for another $30B for PSS. $BMY new headquarters is in Princeton, New Jersey where PSS plane landed yesterday. A deal is coming one way or another.
3 · Reply
Estimize
Estimize Jun. 23 at 8:00 PM
Wall St is expecting 0.24 EPS for $ONC Q2 [Reporting 08/22 BMO] http://www.estimize.com/intro/onc?chart=historical&metric_name=eps&utm_cont
0 · Reply
huggenberg
huggenberg Jun. 23 at 2:52 PM
$IBRX Bioshield (lymphocyte restoration) would be an ideal match to achieve further enhancements of $ONC BCL2xCDK9 dual degrader in chronic lymphocytic leukemia (CLL), and they already have a collaboration for Tislelizumab and Anktiva in NSCLC.
0 · Reply
PrivateTrading
PrivateTrading Jun. 20 at 11:48 AM
$ONC Chronic lymphocytic leukemia (CLL) treatment has experienced tremendous advances over the last decade. The introduction of BTK (Bruton Tyrosine Kinase) inhibitors (Imbruvica, Calquence, Brukinsa) have improved the quality of life of patients (I am in that group). Beigene (trading symbol ONC) has a drug in development that is a BTK degrader. This drug would be a game changer. The drug would degrade (remove/crush) wildtype and multiple mutant forms of BTK, including those that commonly confer resistance to BTK inhibitors in patients who experience progressive disease. Further Eli Lilly (trading symbol LLY) has a drug pirtobrutinib that has a unique method of action. Unlike earlier generations of BTK inhibitors that bind permanently to BTK, pirtobrutinib binds reversibly. This reversible binding allows it to potentially overcome resistance mutations that can develop with other BTK inhibitors. Anyone with CLL will have intriguing treatments if their condition relapses.
1 · Reply
PrivateTrading
PrivateTrading Jun. 20 at 11:18 AM
$ONC A BTK degrader is a game changer. On the other hand, Pirto will be competitive to Brukinsa.
0 · Reply
albiegf13
albiegf13 Jun. 15 at 5:51 PM
$IBRX The only demographic that knows the real value of this outfit are BP CFOs... If I were one, I'd be buying shares... And, it's happening....! If you can't beat them, join them...! $AMGN, $ONC...
2 · Reply
PenkeTrading
PenkeTrading Jun. 12 at 11:44 PM
I found you an Overbought RSI (Relative Strength Index) on the daily chart of BeiGene, Ltd.. Is that bullish or bearish? $ONC #RsiOverbought #NASDAQ
0 · Reply
MaverikIT
MaverikIT Jun. 12 at 4:22 PM
0 · Reply
topstockalerts
topstockalerts Jun. 12 at 3:27 PM
$ONC buyers are stepping in.. ✅ Keep an eye for upcoming plays👀👀
0 · Reply
MaverikIT
MaverikIT Jun. 12 at 2:51 PM
1 · Reply
Latest News on ONC
BeiGene, Ltd. (ONC) Q1 2025 Earnings Call Transcript

May 7, 2025, 2:04 PM EDT - 6 weeks ago

BeiGene, Ltd. (ONC) Q1 2025 Earnings Call Transcript


BeiGene, Ltd. (ONC) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 10:24 AM EST - 4 months ago

BeiGene, Ltd. (ONC) Q4 2024 Earnings Call Transcript


BeiGene to Present at Upcoming Investor Conferences

Feb 25, 2025, 6:01 AM EST - 4 months ago

BeiGene to Present at Upcoming Investor Conferences


3 Biotech Stocks With Notable Insider Buying

Jan 22, 2025, 12:29 PM EST - 5 months ago

3 Biotech Stocks With Notable Insider Buying

AUPH AZN COGT JAZZ XBI ZYME


BeiGene Announces Global Licensing Agreement for MAT2A Inhibitor

Dec 12, 2024, 7:30 PM EST - 6 months ago

BeiGene Announces Global Licensing Agreement for MAT2A Inhibitor


Labcorp CFO Glenn Eisenberg Announces Plans to Retire

Nov 19, 2024, 7:00 AM EST - 7 months ago

Labcorp CFO Glenn Eisenberg Announces Plans to Retire

LH


BeiGene Mourns Death of Beloved Board Member Donald Glazer

Oct 28, 2024, 6:00 AM EDT - 8 months ago

BeiGene Mourns Death of Beloved Board Member Donald Glazer


SeniorVip
SeniorVip Jun. 24 at 1:10 PM
$IBRX $BMY is the one to acquire $IBRX not $AMGN nor $ONC . In 2019, $BMY acquired Celgene which had been acquired Abraxis BioScience in 2010 which was founded by Patrick Soon-Shiong in 2001. It is time for another $30B for PSS. $BMY new headquarters is in Princeton, New Jersey where PSS plane landed yesterday. A deal is coming one way or another.
3 · Reply
Estimize
Estimize Jun. 23 at 8:00 PM
Wall St is expecting 0.24 EPS for $ONC Q2 [Reporting 08/22 BMO] http://www.estimize.com/intro/onc?chart=historical&metric_name=eps&utm_cont
0 · Reply
huggenberg
huggenberg Jun. 23 at 2:52 PM
$IBRX Bioshield (lymphocyte restoration) would be an ideal match to achieve further enhancements of $ONC BCL2xCDK9 dual degrader in chronic lymphocytic leukemia (CLL), and they already have a collaboration for Tislelizumab and Anktiva in NSCLC.
0 · Reply
PrivateTrading
PrivateTrading Jun. 20 at 11:48 AM
$ONC Chronic lymphocytic leukemia (CLL) treatment has experienced tremendous advances over the last decade. The introduction of BTK (Bruton Tyrosine Kinase) inhibitors (Imbruvica, Calquence, Brukinsa) have improved the quality of life of patients (I am in that group). Beigene (trading symbol ONC) has a drug in development that is a BTK degrader. This drug would be a game changer. The drug would degrade (remove/crush) wildtype and multiple mutant forms of BTK, including those that commonly confer resistance to BTK inhibitors in patients who experience progressive disease. Further Eli Lilly (trading symbol LLY) has a drug pirtobrutinib that has a unique method of action. Unlike earlier generations of BTK inhibitors that bind permanently to BTK, pirtobrutinib binds reversibly. This reversible binding allows it to potentially overcome resistance mutations that can develop with other BTK inhibitors. Anyone with CLL will have intriguing treatments if their condition relapses.
1 · Reply
PrivateTrading
PrivateTrading Jun. 20 at 11:18 AM
$ONC A BTK degrader is a game changer. On the other hand, Pirto will be competitive to Brukinsa.
0 · Reply
albiegf13
albiegf13 Jun. 15 at 5:51 PM
$IBRX The only demographic that knows the real value of this outfit are BP CFOs... If I were one, I'd be buying shares... And, it's happening....! If you can't beat them, join them...! $AMGN, $ONC...
2 · Reply
PenkeTrading
PenkeTrading Jun. 12 at 11:44 PM
I found you an Overbought RSI (Relative Strength Index) on the daily chart of BeiGene, Ltd.. Is that bullish or bearish? $ONC #RsiOverbought #NASDAQ
0 · Reply
MaverikIT
MaverikIT Jun. 12 at 4:22 PM
0 · Reply
topstockalerts
topstockalerts Jun. 12 at 3:27 PM
$ONC buyers are stepping in.. ✅ Keep an eye for upcoming plays👀👀
0 · Reply
MaverikIT
MaverikIT Jun. 12 at 2:51 PM
1 · Reply
LongTrainRunning
LongTrainRunning Jun. 12 at 2:03 PM
BeiGene $ONC is up today on announcement of their positive data. $NRIX is taking a beating from that. But I think there's room for both drugs to succeed. Also, if BeiGene gets FDA approval first for their BTK degrader it paves the way for Nurix and increases our chance of approval.
0 · Reply
DonCorleone77
DonCorleone77 Jun. 11 at 8:15 PM
$ONC BeOne says FDA approves table formulation of Brukinsa for approved indications BeOne Medicines announced that the U.S. Food and Drug Administration has approved a new tablet formulation of BRUKINSA for all five approved indications. BRUKINSA remains the leader in new chronic lymphocytic leukemia patient starts across all lines of therapy in the U.S., and for the first time, has become the overall BTK inhibitor market share leader. BRUKINSA tablets have the same efficacy and safety as BRUKINSA capsules based on the results of two single-dose, open-label, randomized Phase 1 crossover studies of healthy adults designed to establish bioequivalence. BRUKINSA is the only BTK inhibitor to offer the flexibility of once or twice daily dosing, with the ability to tailor the schedule to patient needs. It also continues to be the only BTK inhibitor with recommended dosing for severe hepatic impairment. "BRUKINSA's leadership in the U.S. underscores the trust physicians and patients have placed in its differentiated clinical profile," said Matt Shaulis, General Manager of North America, BeOne. "With this new tablet formulation, we are making treatment simpler and more convenient-an important step forward for patients facing certain B-cell cancers."
0 · Reply
Poopoo
Poopoo Jun. 11 at 6:06 PM
$ONC This stock is going to be a beast.
0 · Reply
MaverikIT
MaverikIT Jun. 10 at 1:41 PM
$ZLAB +1.73 - cont on data - eyeing 52wk$ $ONC
0 · Reply
YasirTrades
YasirTrades Jun. 8 at 8:29 PM
GLMD setup looks like $ONC (+40%), $KYMR (+50%), $MLTX (+16% on takeover buzz), and $BPMC (+26% on $9B buyout). GLMD still under $1.40, $12+ book, low float, no dilution. Chart’s coiled. One spark and this can rip. GLMD #biotech #smallcaps #squeeze
0 · Reply
YasirTrades
YasirTrades Jun. 8 at 8:28 PM
GLMD reminds me, this can 10x imo.... of $ONC (+40% on Phase 1 data), $VERV (+29% on cholesterol trial), and $MDCX (+32% YTD vs big pharma). GLMD still under $1.40, $12+ book, low float, no dilution. Just needs a spark. Setup is real. #biotech #smallcaps #squeez
1 · Reply
albiegf13
albiegf13 Jun. 8 at 8:14 PM
$IBRX $ONC & $AMGN VERY
0 · Reply
BioTechHealthX
BioTechHealthX Jun. 8 at 6:31 PM
$ONC With Brukinsa sales soaring and cutting-edge therapies in the pipeline, BeOne Medicines is becoming a dominant force in oncology. https://biotechhealthx.com/biotech-news/beone-medicines-onc-is-quietly-taking-over-the-global-cancer-drug-market/
0 · Reply
BixbyKnolls
BixbyKnolls Jun. 5 at 9:07 PM
$IBRX One of IBRX collaborator featured in IBD today. $ONC https://www.investors.com/research/sp500-biotech-stock-beone-onc-beigene/
0 · Reply
albiegf13
albiegf13 Jun. 4 at 4:46 PM
$IBRX Check out $ONC... Something's happening... Anyone...?
1 · Reply
MaverikIT
MaverikIT Jun. 3 at 3:33 PM
0 · Reply
MaverikIT
MaverikIT Jun. 3 at 3:32 PM
$ONC +5.85
0 · Reply